Characterization of buffy-coat-derived granulocytes for clinical use: - identifying clinical and laboratory parameters for decision making

Characterization of buffy-coat-derived granulocytes for clinical use: - identifying clinical and laboratory parameters for decision making - Biomarker Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50313

Enrollment

200

Registered

2016-05-11

Start date

2016-08-05

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infections neutropenic fever

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • 18 years or older • Admitted to the adult haematology department of the AMC • Diagnosed with a hematological malignancy and receiving high dose chemotherapy, undergoing myeloablative treatment prior to allogeneic HSCT or having intensified immunosuppression due to graft-versus-host disease. • Able and willing to provide written and dated informed consent prior to any study specific procedure

Exclusion criteria

Exclusion criteria: • Patients unable to give written and dated informed consent • Patients younger than 18 years • Patients who had granulocyte transfusions before inclusion

Design outcomes

Primary

Measure	Time frame
Main study parameters/endpoints: • Identification of biomarkers indicating (the course of) neutropenia and neutropenic fever. • A predictive model from laboratory and clinical markers in order to predict the cause of the neutropenic fever. • A model based on the established biomarkers to identify patients suitable for GTX and to determine the individual risk for complications during GTX.	—

Countries

Netherlands

Outcome results